Trial Profile
Ambrisentan in patients with exercise-induced pulmonary arterial hypertension
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Apr 2014
Price :
$35
*
At a glance
- Drugs Ambrisentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- 29 Apr 2014 New trial record
- 11 Sep 2013 Interim results presented at the 23rd Annual Congress of the European Respiratory Society.